Introduction
The commercially available inhaled corticosteroids (ICS) for asthma treatment are beclomethasone dipropionate (BDP), budesonide (BUD),¯unisolide (FLU), uticasone propionate (FP), mometasone furoate (MF), and triamcinolone acetonide (TA); most of them are also available as nasal sprays for the treatment of rhinitis. There is no longer any doubt of their effectiveness in both asthma and rhinitis. Since ICS are widely used in both adults and children, the issue of safety and the risk/bene®t ratio assume primary importance. The present position paper focuses on the clinical and biological aspects of the safety of ICS; therefore, the available literature is reviewed in order to reach experimentally supported conclusions useful for both specialists and general practitioners. Since this position paper speci®cally addresses the subject of safety, other important aspects (e.g., clinical ef®cacy, mode of administration, pharmacokinetic-pharmacodynamic properties, etc.) are not discussed, although relevant reviews are cited.
Asthma is de®ned clinically by reversible airways obstruction and bronchial hyperresponsiveness, and, pathologically, by chronic bronchial in¯ammation involving various cells and mediators (1). The symptomatic relief of bronchospasm is no longer the only therapeutic target. Control of the in¯ammatory component of asthma is equally important, especially for long-term management of the disease. At present, ICS are the most effective drugs for reducing bronchial in¯ammation. Their primary therapeutic role is widely accepted for all types of asthma (1±4). ICS reduce the in¯ammatory in®ltrate in the bronchi (5±11) and, at least in part, reverse the anatomical alterations in the bronchial wall usually detected in asthma (12, 13). Although ICS are highly effective in controlling symptoms and bronchial in¯ammation, clinical relapse and the reappearance of bronchial in¯ammation are usually observed after their discontinuation (14±17). Therefore, long-term treatment for effective asthma control is usually required.
The mechanism of action of glucocorticoids involves binding to a speci®c intracytoplasmic receptor that subsequently migrates into the nucleus and modulates the transcription of speci®c target genes. These genes encode for cytokines, lipocortin-1, endothelin, b-adrenoceptors, iNOS, endopeptidases, etc. Several transcription factors are involved in this mechanism (18±24). ICS exert their clinical and anti-in¯ammatory actions directly on the bronchial wall; therefore, these effects depend upon a wide range of variables, including the status of the bronchial wall (12, 13, 25), the pharmacodynamic-pharmacokinetic properties of the drug (26±30), the delivery system (31±34), the patient's cooperation (35±38), and the dosage regimen (39±41). These factors also determine the severity and frequency of side-effects.
Systemic side-effects
The more relevant systemic side-effects of ICS concern adrenal gland function, bone metabolism, and growth pattern in children/adolescents. Due to the widespread use of ICS, these side-effects have been extensively investigated in several controlled studies by means of biochemical, metabolic, and morphofunctional parameters. The occurrence and severity of these side-effects depend, as mentioned above, upon a large number of variables, including the characteristics of the drug (lipophilicity, pharmacokinetics, and pharmacodynamics) and the mode of administration (dose, delivery system, coordination, etc.). Therefore, it is often dif®cult to reach an unequivocal conclusion; nevertheless, based on consistent experimental evidence, some useful suggestions can be provided (42).
Hypothalamic-pituitary-adrenal axis (HPAA)
Long-term treatment with oral corticosteroids may result in signi®cant suppression of the HPAA: exogenous steroids, through negative feedback, suppress corticotrophin secretion, thus leading to adrenal cortex atrophy and to subsequent decrease of cortisol secretion (43). This effect is pronounced and longlasting with oral corticosteroids. ICS may also have some measurable effect on the HPAA (44). Since ICS are used for long-term treatment, assessment of their effects on the HPAA is of primary relevance from the viewpoint of safety.
There are several standardized methods for assessing the integrity of the HPAA both in static and dynamic conditions. They include morning cortisol, ACTH levels, integrated (AUC) cortisol levels overnight, free urinary cortisol level over 24 h (usually with creatinine correction), ACTH (tetracosactrin) stimulation, the metyrapone test, and insulin-induced hypoglycaemia (45±47). A single morning cortisol level is weakly sensitive due to wide variations of this variable in the same subject. The integrated overnight cortisol measurement can detect also the disappearance of physiological peaks of secretion; therefore, it is a reliable test, although it requires multiple blood sampling. The free urinary cortisol over 24 h appears to be a practical and reliable index, since it provides a global evaluation of the adrenal function, and it is not in¯uenced by circadian changes in cortisol blood levels (45±51); however, obtaining a complete 24-h urine sample may be problematic. The dynamic tests assess the integrity of the whole HPAA, but they can be performed only in selected centres and they often cause discomfort to patients; therefore, they are not commonly used for clinical trials.
Some studies have been performed in healthy subjects. In one, it was shown that BDP exerted a greater (approximately twofold) suppressive effect on the HPAA than BUD, in a single dose (200, 800 , or 3200 mg) (52). In another one, BUD 400 mg single dose, or 400 mg b.i.d. for 2 weeks, signi®cantly suppressed the adrenal function (53). Two doseresponse studies (54, 55) showed that FP (up to 2000 mg/day) is more potent in reducing the daily plasma cortisol level (dose-dependent) than BUD (up to 1600 mg/day), although it is dif®cult to compare the dosage of two different molecules. Grove et al. (56) found a signi®cant effect on the ACTH test by FP (750±1500 mg) and BUD (800±1600 mg) with no difference between the drugs. Wilson et al. showed that both FP (average 1625 mg/day) and TA (1600 mg/ day) suppressed the urinary cortisol excretion, but only FP affected plasma cortisol levels (57). On the other hand, studies by Braun et al. (58) found that BDP and BUD at high dosages (>2000 mg) did not signi®cantly affect urinary free cortisol levels, if administered by a large-volume spacer.
When administered at high dosages (>1200 mg in adults or >800 mg in children), BDP exerted a signi®cantly more prominent effect on the HPAA than BUD, and this effect was dose-related (59±62). Nevertheless, the inhibitory action on the HPAA by BDP and BUD was found to be, respectively, eight-and ®vefold lower than that by systemic prednisone (63). In two studies (64, 65) assessing the integrated cortisol level in children, BDP 1000 mg affected the physiological rhythm of cortisol secretion. In another study in children, BUD (200, 400 , and 800 mg/day) did not affect the urinary cortisol (66). In a long-term study (1 year) on moderate to severe asthma, FP (1500 mg/day) was demonstrated to be more effective than BDP and devoid of effects on the HPAA (67). Langdon & Capsey (68) reported that FP (400 mg/day) given as a dry powder was as effective as BUD (800 mg/day) and did not affect the morning blood cortisol level of adult asthmatics. On the contrary, in another study, FP (2000 mg/day) exerted a signi®cantly more pronounced inhibitory effect on the HPAA than BDP (1600 mg/day) in adults (69). In a single-dose, dose-response comparative study by Clark et al., FP (2000 mg) was shown to be threefold more potent than BUD (2000 mg) in reducing the overnight urinary cortisol excretion (70); a superimposable result was obtained in children with FP and BUD up to 1250 mg/day (71) and in adults on chronic treatment (72). In a long-term study in asthmatic children (up to 5 years), Volovitz et al. (73) demonstrated that BUD (200 mg/day) did not signi®cantly in¯uence HPAA function. The administration of 400 mg/day of BUD or BDP for 2 weeks in asthmatic children resulted in a reduction of free urinary cortisol, without differences between the two compounds (74). Similar results (75) were obtained with the same drugs at higher doses (>400 mg/day). Interestingly, a controlled study on asthmatic children receiving 250±1000 mg/day BDP showed that a signi®cant reduction of 24-h urinary cortisol occurred in patients using a metered-dose inhaler (MDI), but not in those using a spacer device (76). Similar results were obtained in children receiving BUD (100 mg b.i.d.) or FP (200 mg b.i.d.) through a spacer, in whom no adrenal suppression was seen (77); the same effect was also observed with BUD up to 400 mg/day administered through a spacer device (78), whereas FP 200±400 mg/day and BUD 400 mg/day by Turbohaler/Diskhaler reduced the urinary free cortisol excretion (79). No signi®cant effect on the HPAA was observed with FP (100±200 mg/day) (80) in a long-term study performed on asthmatic children. High doses of FLU and TA (>1000 mg/day) appeared to have no effect on free urinary cortisol (81, 82). FP and BUD 400 mg/day for 4 weeks did not affect the plasma cortisol levels in asthmatic children, although FP showed a slightly more pronounced effect (83). A recent meta-analysis study conducted on FP, BUD, and BDP showed that FP and BDP did not affect plasma cortisol levels, while a signi®cant reduction was observed with BUD (84). Finally, some clinical trials have con®rmed the safety of ICS-only treatment in children (85, 86), and a recovery of adrenal function after oral steroid reduction and introduction of ICS (87±89). The results are summarized in Table 1 .
Most available papers refer to BUD, BDP, and FP. These drugs can in¯uence the HPAA in a dosedependent manner (the effect can often be detected even after a single dose). This effect seems to occur when doses of >800 mg/day in adults and >400 mg/ day in children are used (90). Finally, acute adrenal failure consequent on ICS withdrawal (91, 92) or Cushing's syndrome (93, 94) has been reported only anecdotally.
In conclusion, the effects of ICS on the HPAA can be detected only by using sensitive biochemical methods; therefore, it is dif®cult to demonstrate their clinical counterpart and their clinical signi®cance: in none of the controlled studies were signs or symptoms of adrenal failure described.
Bone metabolism (Table 2) Oral corticosteroids may induce osteoporosis and increase the risk of fractures in adult patients (95±97). The effects of corticosteroids on bone metabolism mainly involve the trabecular structure and are mediated by a number of mechanisms at different sites of action (96). Firstly, corticosteroids reduce intestinal calcium absorption and enhance its renal excretion; these actions result in compensatory secretion of parathormone, bone resorption, and increased activity of osteoclasts. Secondly, corticosteroids inhibit osteoblastic activity and the synthesis of osteocalcin. Thirdly, steroids reduce the synthesis of adrenal cortex-derived oestrogens. This last ®nding partly explains the increased risk of osteoporosis in postmenopausal women (98, 99). Once again, since ICS are frequently used at high doses and for long-term treatment, a careful evaluation of their effects on bone is required (99, 100).
These effects are commonly assessed by biochemical methods (Table 3) , which evaluate calcium metabolism (calcium, phosphate, and parathyroid hormone) and the enzymatic activities involved in bone turnover and some products of bone catabolism. They include serum osteocalcin, alkaline phosphatase, procollagen I carboxyterminal propeptide (PICP), procollagen III N-terminal propeptide (PIIINP) (as indices of bone synthesis), urinary hydroxyproline, urinary calcium, serum pyridine cross-links, and type I collagen carboxyterminal telopeptide (ICTP) (as indices of bone resorption) (101±104). Bone density can also be assessed by dual X-ray absorptiometry (DEXA) or ultrasound densitometry of skeletal segments (105); generally, the lumbar spine and the neck of the femur are studied.
Also in this case, the majority of data are available for BDP, BUD, and FP; therefore, no conclusive statement can be given on the other compounds. In general, experimental evidence does not support an increased risk of osteoporosis or pathologic fractures in either adults or children (106±108). Short-term studies, all performed with moderate to high doses of BUD or BDP, showed a decrease in serum osteocalcin and increased urinary hydroxyproline; these effects were strictly dose-related (109±111). High doses of BUD (1600 mg/day) when administered through spacers to premenopausal women did not in¯uence osteocalcin, while BDP (2000 mg/day) did so (112). The reduction of serum osteocalcin exerted by BDP (500 mg b.i.d.) was less marked than with prednisolone (15 mg/day) in a 
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7-day course of therapy (113) , and it could be minimized by using a large-volume spacer (114) . Toogood et al. (115) demonstrated that long-term treatment with BDP or BUD (1000 mg/day or more) did not signi®cantly affect either bone density or the risk of bone fracture if administered through spacers. Neither FP (1000±2000 mg/day) nor BUD (1600 mg/day) signi®cantly reduced serum osteocalcin (116) . In children, BUD (800 mg/day) and BDP (800 mg/day) did not alter any biochemical marker of bone metabolism (117, 118) . BDP (300±400 mg/day) in asthmatic compared to normal children did not have any detectable effect on bone density (119) . These results were con®rmed in several other controlled studies with BUD and BDP in asthmatic children (120±122). Similarly, in a long-term treatment with BDP (200±400 mg/day), no signi®cant detectable effect on bone mass was observed in adolescents (123) . Although an increase in urinary phosphate and a reduction in serum osteocalcin concentrations were observed, no change in bone density was detectable in adult patients taking ICS at high dosages (BUD or BDP >800 mg/day) for up to 18 months (124) . No changes in serum procollagen type I telopeptide were observed in patients receiving BUD or BDP (800 mg/day) for more than 2 years (125). On the other hand, a slight reduction in collagen types I and III turnover was seen with BUD and BDP 800 mg/day (126), while BUD 400 mg/day only reduced the turnover of type III collagen (127) . Bootsma et al. (128) compared the effects of FP (750 mg/day) and BDP (1500 mg/day) in asthmatics after short courses of treatment; they found that BDP, but not FP, affected the serum osteocalcin levels. In asthmatic children, FP and BUD 400 mg/day did not affect the markers of bone resorption and formation (83). Finally, Martinati et al. (129) found no change in the bone mass density, measured through absorptiometry, of asthmatic children treated for 4 months or more with BDP (150±400 mg/day).
Although certain effects of ICS on bone metabolism are detectable, they are evident only by laboratory assessment, when high doses are used. In particular, in none of the studies assessing bone mass density was a signi®cant effect found (Table 2 ). Moreover, in several studies, the confounding effects of short courses of oral steroids have also to be taken into account. The clinical relevance of the effects on bone metabolism is questionable, since an increased risk of fractures or osteoporosis has never been substantiated. However, in view of the documented bioavailability of high-dose ICS and possible effects on the HPAA, it is advisable to use the lowest effective doses to maintain asthma control.
Growth in childhood (Table 4) Since ICS are widely prescribed in paediatric patients, often for long-term treatment, their possible effects on growth pattern have been carefully investigated. Untreated asthma itself signi®cantly affects the growth and ®nal stature of children, as was clearly documented as early as 1868 (130) . This was subsequently con®rmed in prospective studies, which showed that asthma may reduce the growth pattern of children and may reduce their potential height or, at least, the growth velocity (131±134). The growth deceleration seems to correlate well with the pulmonary function impairment (134). Until 1980, the only objective measurement of children's growth was long-term height measurement, which is imprecise in the short term and may be affected by a wide individual variability. In 1980, knemometry was introduced (135) . This method measures the length of lower legs and is able to detect minimal changes, even within days. Therefore, knemometry is presently considered a reliable method for short-term assessment of growth and growth velocity.
When evaluating the effects of ICS on growth, we must keep in mind that the main outcome is the ®nal (expected) height, rather than the growth speed by itself. In fact, the clinical studies evaluating the longterm growth of children taking BUD or BDP did not demonstrate impairment of the ®nal height (85, 73, 136±140). Moreover, FP 200 mg/day did not affect longterm growth (141); growth retardation was seen only in children taking oral steroids (142). In two separate studies, Agertoft & Pedersen (143) and Merkus et al. (144) found that BUD did not affect growth velocity or long-term statural growth. FP at doses of 50±200 mg/ day did not impair long-term growth (145, 146). On the other hand, Wolthers & Pedersen (147, 148) reported a signi®cant reduction of short-term growth with BUD 800 mg/day, but not with 400 mg/day, and similar results were obtained by Agertoft & Pedersen (79). In another study, FP 200 mg/day did not affect knemometric growth, while BDP 400 and 800 mg/day did so (149). BUD (800 mg/day) impaired growth velocity as measured by knemometry, and the impairment correlated well with the suppression of types I and III collagen turnover (150). Superimposable results were obtained in a similar study with BDP 400 and 800 mg/day (151). Signi®cant growth reduction was reported by Doull et al. in prepuberal children receiving inhaled BDP (152) . Similarly, in a recent double-blind, placebocontrolled study (153) , a reduction of linear growth was observed in children treated for 1 year with BDP 400 mg/daily. By contrast, a recent meta-analysis study including 21 trials concluded that long-term BDP did not exert a signi®cant effect on the attained height (compared to the expected) in children (154) .
The available data suggest that short-term growth may be affected by high doses of ICS, but growth velocity and stature seem to depend strictly on the degree of asthma control. In fact, asthmatic children receiving ICS seem to reach their predicted height eventually. Nevertheless, this potential systemic sideeffect imposes cautious use in children: the lowest effective dose must be used, and stature should be regularly monitored.
Local side-effects
Unwanted effects of the topical administration of ICS are usually de®ned as``local side-effects'', and they include oropharyngeal candidiasis, dysphonia, cough/ bronchospasm, and, rarely, contact allergy. The active principles themselves, rather than the excipients, seem to be responsible for these events (155±157). Occasionally, side-effects have also been attributed to the excipients (158) . The prevalence of local side-effects depends upon several factors: inhalation technique, use of spacer chambers, the chemical characteristics of the drugs, the type of excipient, and the duration and dosage of treatment (31, 33, 155) . Although a frequent topic of speculation, there is no evidence of increased risk of viral infections in patients taking ICS (159) .
Candidiasis
Oropharyngeal candidiasis is probably due to a compromise of local immune responses caused by ICS (157) ; in fact, the immunosuppressant action of corticosteroids has been well documented both in vitro and in vivo. In assessing studies, simple colonization (i.e., positive culture without signs or symptoms) should be distinguished from the true infection (positive culture with local signs and symptoms); this fact may affect the interpretation of experimental data.
In adult patients treated with BDP up to 800 mg/day and for less than 6 months, the occurrence of Candida colonization (40% of subjects) did not signi®cantly differ from that observed in control groups, whereas clinical infection was observed in about 5% of cases (160±164). The rate increased with higher doses and during long-term treatment (up to 77% of patients) (165, 166) . Candidal infection in children, also on longterm BDP, is generally lower than in adults, but it increases when the daily dose exceeds 800 mg (167±169). In one study, BDP (up to 2000 mg/day) was associated with candidiasis in 3±4% of patients when employed for less than 3 months; the percentage rose to 40% after 1 year of treatment (169, 170) . Sparse data are available for FLU and BUD (171±174). Three cases of oesophageal candidiasis have been described (171) . In a study with FLU (1600 mg/day), the occurrence of oropharyngeal candidiasis was lower with a twice daily regimen than with q.i.d. administration (172) . High-volume spacers seem to reduce both colonization and infection rates markedly (173±175).
Dysphonia
Dysphonia (alone or in association with sore throat) is an important local side-effect observed with long-term treatment with ICS. It is usually unrelated to oral candidiasis (156, 157) . Dysphonia is probably the result of a nonspeci®c myopathy of the laryngeal muscles similar to that observed in hypothyroidism (176, 177) . Dysphonia has been reported to occur with a frequency of 20±50% of adult patients consuming less than BDP 600 mg/day and up to 72% for doses up of 1600 mg/day or more (156, 160, 167, 177) . As far as BUD and FLU are concerned, the experimental results are sparse and controversial, but they agree on the dose-dependency of the side-effects (156, 173, 174) .
Dysphonia seems to be due to the active drug rather than to propellants or excipients. Rinsing the mouth after inhalation and reducing the dose appear to be reasonable precautions. The use of spacers cannot be considered an effective preventive measure, but speci®c studies on this particular topic, and also on the reversibility of dysphonia, are still lacking.
Cough and bronchospasm
These unwanted effects seem to be strictly related to bronchial hyperreactivity (178, 179) . They appear to be due to propellants (179, 180) rather than to active principles (158) . With BDP, cough alone has been reported to occur in 30±40% of cases, while cough and bronchospasm occur in about 20% of patients (155, 181) ; deep-inspiration-induced bronchospasm has been proposed as a possible pathogenic mechanism (182) . Only sparse reports are available for BUD (183) , and this side-effect is usually described as of minor relevance. Cough and bronchospasm can be avoided or minimized by premedication with b 2 -agonists or, preferably, by using powdered preparation rather than pressurized aerosols.
Contact allergy
Episodes of perioral eczema and mucosal oedema have been reported, but only with BUD (184±189). In some cases, positive patch tests for BUD, and not the excipients, have been described, suggesting a type IV hypersensitivity reaction (185±187). In two cases, a concomitant patch positivity to other substances was described (188, 189) . Contact allergy occurs only occasionally and must be considered a very rare sideeffect.
In conclusion, oropharyngeal candidiasis may occur in prolonged treatments, but simple precautions (using spacer and rinsing mouth) can minimize this adverse event. On the other hand, dysphonia may represent a troublesome side-effect, usually requiring treatment discontinuation.
Other systemic side-effects
Side-effects that are well known to occur with systemic steroids have also been sporadically described with ICS. Insomnia, hyperactivity, aggressiveness, and depression have been described in seven patients on inhaled BUD (190±192); these effects occurred in the early days and disappeared after discontinuation. No predictive parameter is known for psychic effects (193) .
It is known that long-term treatment with systemic steroids may induce an increased risk of posterior subcapsular cataract or open-angle glaucoma; these side-effects are very rare with ICS (194) . The safety of ICS for the eye has been well documented in children in two studies (195, 196) , in which the use of ICS was not associated with an increased risk of cataract formation. Another large prospective study in adults (197) , including long-term treatments and a wide range of doses, excluded the risk of cataract. A slightly increased risk of glaucoma was found in a population of patients (age >65 years) receiving high doses of ICS (198) . So far, a single case of open-angle glaucoma and one of cataract have been reported with high-dose BDP in long-term treatment (199, 200) .
Skin thinning and increased capillary fragility may occur in the elderly, especially women, who use high doses of ICS for long periods (201, 202) . A questionnaire-based study reported that skin problems occur frequently in about 6% of patients (203) . This observation is of speculative interest; nevertheless, longterm survey studies are needed for a practical measure of the problem. In addition, one case of angina bullosa haemorrhagica (204, 205) and four cases of acne have been reported (206) .
No signi®cant effect on glucose metabolism has been shown for ICS, even with high doses (up to 2000 mg) of BDP (207±209). In one study performed in asthmatic children, BUD (800 mg/day) was reported to increase HDL-cholesterol levels in a subset of subjects, but no signi®cant changes in total cholesterol were observed (210) .
An increase in neutrophil counts in the peripheral blood of patients taking ICS has been noted (211) . Similar effects have been sporadically described with BDP up to 1600 mg/day, but the clinical relevance of this effect is questionable (212). BUD at high doses (1600 mg) caused a reduction of hypodense eosinophils in peripheral blood (213) . Finally, in a recent study on children, BDP (600 mg/day or more) did not affect cellular immunity parameters (T and B cells and IL-2 secretion) and did not increase the risk of infections (214) .
In conclusion, the safety of ICS for the eye seems to be substantiated, and no signi®cant effect on lipid and glucose metabolism is to be expected. Some caution has to be exercised in the elderly taking high doses of ICS for long periods, since skin thinning and increased capillary fragility may occur in a low percentage of patients.
Safety of ICS in pregnancy and lactation
Uncontrolled asthma may per se constitute a risk of foetal hypoxemia with subsequent increased rate of perinatal death; furthermore, it may aggravate gestative hypertension and eclampsia (215±217). Therefore, the correct treatment of asthma in pregnant women should be the most important therapeutic aim.
Safety of corticosteroids
As far as corticosteroids are concerned, some risk of teratogenicity has been evidenced only in animal models (cleft palate in rats) with BDP and TA (218, 219) ; nevertheless, no actual teratogenicity in man has ever been reported. There are sparse experimental and controlled data on the safety of ICS in pregnant women, obviously due to the ethical limitations which such studies impose. Some data are available for BDP administered to asthmatic pregnant women (220, 221) : the drug appeared to have no effect on the pregnancy's outcome and not to increase the risk to the foetus. The increased rate of prematurity and low birth weight were probably due to the effects of asthma itself rather than to ICS (222) . On the basis of clinical experience and the available data, BDP has been proposed as the ICS of choice for treating asthma in pregnancy (223, 224) . Concerning the risks for pregnancy, the US Food and Drug Administration (FDA) classi®es BDP, BUD, and FLU as class C (``risk cannot be ruled out; human studies are lacking and animal studies are positive or lacking as well''), and TA as class D (``positive evidence of risk; investigational or postmarketing data show risk to the foetus'') (223) . No speci®c study has been conducted on ICS and lactation. Based on pharmacokinetic data, BDP can be excreted in milk; nevertheless, the therapeutic doses employed are not expected to result in signi®cantly high concentrations (225, 226) . The risks of uncontrolled asthma in pregnancy are well recognized, as is the ef®cacy of ICS. Therefore, it is advisable to treat asthma optimally in pregnant women; when indicated, ICS should be used at the lowest effective dose. BDP, for which more data are available, should be preferred.
Nasal corticosteroids
Nasal corticosteroids are mainly used for the management of rhinitis, but surprisingly few objective data on their safety are available. As the dosage used intranasally is low compared to inhaled corticosteroids for asthma therapy, it may be expected that the risk of systemic adverse effects is correspondingly reduced. However, the absorption dynamics from the nose and the bronchi have not been studied so far, so that this conclusion cannot be easily drawn. Furthermore, there is presently an increasing clinical indication for the combined use of corticosteroids in rhinitis and bronchial asthma, as these diseases are often associated; thus, additive side-effects due to the drugs may occur. Local side-effects such as crusting and epistaxis have also been discussed and may partially be due to the use of Freon propellants in former years.
Systemic side-effects (Table 5) BDP was introduced about two decades ago ®rst as pressurized intranasal spray, then as aqueous suspension, and very recently as unpressurized powder: many clinical studies and patient evaluations have been done since then. A 30-year review of the available literature was recently provided by Edelman & van Os (227) . Intranasal doses of up to 400 mg a day have not been associated with suppression of the HPAA when given for up to 6 months. Only one case of adrenal suppression has been reported in the literature. Furthermore, doses of 400 mg/day or less of BDP have not been associated with osteoporosis or risk of fractures, and one study in children with seasonal allergic rhinitis did not show any effect of intranasal BDP on bone metabolism. In seven studies, including 762 patients treated with BDP up to 400 mg per day for at least 12 weeks, none of the patients had positive Candida cultures from the nose or clinical manifestations of Candida infection. In some case reports of posterior subcapsular cataracts, the majority of patients either had used BDP for more than 5 years (often exceeding the recommended dosages), or had received systemic corticosteroids. Moreover, the development of ocular hypertension or open-angle glaucoma after intranasal corticosteroid use was limited to two patients, in whom the pressure returned to normal after the discontinuation of BDP. In a recent case control study involving nearly 10 000 patients, the authors reported no increased risk of ocular hypertension or open-angle glaucoma even after high doses of nasal corticosteroids (more than 200 mg FP or more than 400 mg BDP, BUD, or TA daily) (196) .
In a comparative trial involving terfenadine and nasal FP (200 mg/day), the morning plasma cortisol concentration was assessed and no effect on this parameter was demonstrated (228). Treatment of seasonal allergic rhinitis with once-daily intranasal FP in children for 4 weeks did not affect the 24-h urinary excretion of free cortisol and 17-ketogenic steroids compared to placebo (229) . In a third study, nasal FP (200 mg twice daily) was demonstrated not to affect urinary cortisol levels (230) . In a placebo-controlled study in patients with perennial rhinitis, the administration of 200 mg once daily FP for 1 year did not affect bone mineral density or biochemical markers of bone turnover, it did not signi®cantly affect the HPAA, and lastly there was no evidence of posterior subcapsular cataract or glaucoma (231) . A 12-month double-blind, placebo-controlled study in patients with perennial allergic rhinitis showed that FP provoked no change in nasal epithelium (assessed by biopsy) and did not modify the plasma and urinary cortisol level (232) . In an open 12-month study with 400 mg BUD or BDP per day, no signi®cant change in haematology, blood chemistry parameters, or plasma cortisol levels was found (233) . Intranasal BUD (200±400 mg/day) administered for 1 year was seen not to cause either mucosal atrophy or HPAA impairment (234) . Similarly, in a study lasting up to 5.5 years, the continued use of BUD had no measurable effect on the HPAA and did not alter nasal epithelium (235) . The possible side-effects of TA (110 or 220 mg/day) aqueous nasal spray and oral prednisone on the HPAA were assessed in a study of male rhinitic subjects (236) . Morning plasma cortisol level, urinary cortisol, and ACTH stimulus were evaluated, and no signi®cant effect of the nasal corticosteroid on these parameters was found. No meaningful changes of morning serum cortisol levels were recorded in 93 patients with allergic rhinitis taking TA (110, 220, and 440 mg/day) for more than 1 year (237) . The lack of effects on the HPAA by TA was further con®rmed in three medium-term studies on adult patients (238±240). In a recent crossover controlled study (241) , 5-day courses of BUD, MF, and TA at clinically recommended doses did not affect the HPAA, bone metabolism, or blood white cells.
However, some measurable effects of nasal corticosteroids have also been reported. Wihl et al. reported that BUD 400 and 800 mg single dose (but not BDP) affected urinary cortisol; the data were con®rmed with the same drugs after a 4-day course (242) . In a recent study conducted in healthy volunteers with a 4-day course of different nasal steroids, FP (200 mg/day mg/ day), but not TA (220 mg/day) or BDP (336 mg/day), affected overnight urinary cortisol; on the other hand, none of the drugs affected serum cortisol and the ACTH response (243) . Beclomethasone nasal spray (mean dose 168 mg b.i.d.) up to 12 months was reported not to affect the HPAA; nevertheless it exerted a small but signi®cant effect on the growth of children aged 6±9 years (244) . By means of knemometry, Wolthers & Pedersen demonstrated that 4-week treatment with intranasal BUD (200 or 400 mg/day) did not signi®-cantly affect growth velocity, although a trend toward reduction was seen with 400 mg/day (245) . However, in another study comparing terfenadine 60 mg/day, budesonide 200 mg/day, and depot methylprednisolone 60 mg, a signi®cant reduction of growth velocity was seen over 6 weeks in those children receiving nasal and systemic steroids (246) .
A recent review summarized more than 20 clinical trials involving more than 6000 patients treated with (250) . Finally, a single case of hyperactivity and disturbed behaviour after nasal BDP has been so far described (251) . In summary, intranasal corticosteroids are highly effective; nevertheless, they are not completely devoid of systemic effects. Thus, care has to be taken, especially in children, when long-term treatments are prescribed.
Local side-effects
Again, the longest experience of local side-effects is available for BDP (227) . Since local application of corticosteroids may cause dermal atrophy, the possibility of mucosal atrophy by long-term use of intranasal steroids has been thoroughly investigated.
In several studies, including chronic use of intranasal BDP for periods of up to 36 months, biopsy investigations did not show any effect on nasal mucosa. The safety of once-daily administration of 220 mg/day of TA for 3 weeks was evaluated in 429 patients with seasonal allergic rhinitis compared to the placebo group, showing no signi®cant difference between the two groups (252) . Similar results were obtained in a multicenter study evaluating the safety of a once-a-day regimen of 110, 220, and 440 mg TA administered to patients with perennial allergic rhinitis, aged 12±65 years (253) . A further study of adult patients with perennial allergic rhinitis treated for 12 months with MF (200 mg/day) showed in nasal biopsies no adverse tissue change after treatment (254) . Similarly, no signi®cant effect of MF (200 mg/ day) on mucociliary clearance and olfactory function was detectable (255) . The data further indicated that some of the adverse events such as irritation, crusting, itching, and stinging may be due to the propellant used in older formulations rather than to the active drug. Epistaxis (including blood-containing secretions) was in some studies reported to be more frequent (about 15%) in the active than in the control group (227, 256) ; in other studies, it was not (257, 258) . It is advisable that patients on long-term therapy have their nasal mucosa periodically examined; such patients may use an inert ointment after the use of the steroid to protect mucosa from drying. The application once daily of intranasal steroids may possibly reduce these minor side-effects.
In conclusion, although the available studies on intranasal steroids show favourable results, local sideeffects could be reduced by teaching the right application technique. Long-term use should be periodically monitored.
Conclusions
ICS are presently the most effective drugs for the treatment of bronchial asthma (1±4), since they dramatically reduce the in¯ammatory phenomena underlying the disease; similarly, nasal corticosteroids are a ®rst-choice treatment for rhinitis (259) . ICS exert their effects by acting on several components of in¯ammation and they modify the anatomopathologic features of the in¯ammatory process in most cases. For these reasons, ICS are widely used and prescribed in both adults and children, usually in long-term treatments. Therefore, the safety of these drugs is of importance for both general practitioners and specialists.
According to the available controlled studies, some effects on the HPAA and bone metabolism are detectable with high doses of ICS. Indeed, the effects on the HPAA and bone metabolism are measurable only by means of biochemical parameters; their clinical signi®cance is still unknown and is probably extremely small compared to the bene®t achieved. With regard to children's growth, some data suggest that short-term growth can be affected by high doses of ICS, but this effect is certainly less signi®cant than that due to uncontrolled asthma. It is often dif®cult to separate the effects of asthma and ICS. Stature and growth velocity seem to depend mainly on the degree of asthma control (134, 260) , and children receiving ICS seem to reach eventually their predicted height. Nevertheless, the potential of systemic side-effects imposes, especially in children, a cautious use: it is advisable to use the lowest effective dose and, when an MDI is used, it should be in combination with a large-volume spacer.
Some local side-effects have also been described. Oral candidiasis seems to be dose-related and can be minimized by using spacers and rinsing the mouth after inhalation, whereas dysphonia, if troublesome, may require discontinuation of treatment. Other systemic side-effects have also been described: cutaneous side-effects may be of some relevance in the elderly, whereas neurologic and ocular adverse events have to be considered anecdotal.
ICS, together with avoidance of trigger factors and use of rescue bronchodilators, remain the ®rst-choice therapeutic option for the management of bronchial asthma, and their risk/bene®t ratio is, overall, favourable. This does not imply that ICS are totally safe: in fact, a class relabelling for ICS has been recently approved in the USA (261, 262) , and the British Committee on Safety of Medicines (CSM) (263) has also emphasized some warnings. A careful evaluation of patients (especially those taking high doses for long periods) is always required. Similar considerations are valid also for nasal corticosteroids: the risk/bene®t ratio is generally favourable, but special caution has to be exercised in children, since systemic side-effects have been described. 
